Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 18

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 18
---
 information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing.

The number of shares of common stock to be outstanding after this offering as shown above is based on 8,702,719 shares of our common stock outstanding as of March 31, 2025, and excludes:

| ● | 672,576 shares of common stock issuable upon the exercise of options outstanding under the 2015 Plan, as of March 31, 2025, with a weighted average exercise price of $11.93 per share; |

<div align='center'>S-12</div>

| ● | 165,160 shares of common stock issuable upon the exercise of options outstanding under the 2018 Plan, as of March 31, 2025, with a weighted average exercise price of $19.65 per share; |

| ● | 71,712 shares of common stock issuable upon the exercise of options issued as inducements material to new employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), as of March 31, 2025, with a weighted average exercise price of $12.40 per share; |

| ● | 67,316 shares of common stock that were reserved for issuance as of March 31, 2025 under our 2018 Plan; and |

| ● | 2,609,289 shares of common stock issuable upon exercise of outstanding warrants, at a weighted average exercise price of $39.58 per share. |

To the extent that any shares are issued upon the exercise of outstanding options or warrants or new options issued under our equity incentive plans or otherwise pursuant to any grants made in the future under our equity incentive plans (including any equity incentive plans we may adopt in the future), you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to our stockholders.

<div align='center'>S-13

PLAN OF DISTRIBUTION</div>

We have entered into a Sales Agreement with Leerink Partners, under which we may issue and sell from time to time up to $50,000,000 of our common stock through or to Leerink Partners as our